Literature DB >> 27366528

Anaesthesia Management and Use of Sugammadex in a Patient with Ullrich's Disease.

Emre Erbabacan1, Güniz M Köksal1, Tuğçe Barça Şeker1, Birsel Ekici1, Rahsan Özcan2, Fatiş Altindaş1.   

Abstract

Here, we report anaesthesia management and the successful use of total intravenous anaesthesia and sugammadex in a patient with Ullrich's disease. Propofol and remifentanyl infusion was used for anaesthesia. After the end of the surgery, when the train-of-four value was 0%, 4 mg kg(-1) sugammadex was administered, and the patient was successfully extubated after 36 s. No adverse effects or safety concerns were observed. In conclusion, we suggest that the use of propofol infusion to avoid the use of inhalation anaesthetics and the use of sugammadex for the reversal of the effects of rocuronium is safe in patients with Ullrich's disease.

Entities:  

Keywords:  Sugammadex; muscular dystrophy; total intravenous anaesthesia

Year:  2015        PMID: 27366528      PMCID: PMC4894239          DOI: 10.5152/TJAR.2015.22448

Source DB:  PubMed          Journal:  Turk J Anaesthesiol Reanim        ISSN: 2149-276X


  13 in total

1.  The use of sugammadex in a patient with myotonic dystrophy.

Authors:  Yuka Matsuki; Munetaka Hirose; Mari Tabata; Yasunari Nobukawa; Kenji Shigemi
Journal:  Eur J Anaesthesiol       Date:  2011-02       Impact factor: 4.330

2.  Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.

Authors:  Hans D de Boer; Jan van Esmond; Leo H J D Booij; Jacques J Driessen
Journal:  Paediatr Anaesth       Date:  2009-10-23       Impact factor: 2.556

3.  Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study.

Authors:  Iben F Sorgenfrei; Kathrine Norrild; Per Bo Larsen; Jakob Stensballe; Doris Ostergaard; Martine E Prins; Jørgen Viby-Mogensen
Journal:  Anesthesiology       Date:  2006-04       Impact factor: 7.892

4.  Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge records.

Authors:  Guohua Li; Joanne E Brady; Henry Rosenberg; Lena S Sun
Journal:  Paediatr Anaesth       Date:  2011-07-02       Impact factor: 2.556

5.  Anesthetic management of a child with Ullrich myopathy.

Authors:  Irina Grosu; David Truong; Simona Teodorescu; Maryline Mousny; Francis Veyckemans
Journal:  J Anesth       Date:  2012-04-08       Impact factor: 2.078

6.  Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.

Authors:  Ozlem Sacan; Paul F White; Burcu Tufanogullari; Kevin Klein
Journal:  Anesth Analg       Date:  2007-03       Impact factor: 5.108

Review 7.  Joint hypermobility as a distinctive feature in the differential diagnosis of myopathies.

Authors:  N C Voermans; C G Bonnemann; B C J Hamel; H Jungbluth; B G van Engelen
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

8.  Perioperative care of a child with Ullrich congenital muscular dystrophy.

Authors:  Neesann Puangsuvan; Robert A Mester; Venkataraman Ramachandran; Joseph D Tobias
Journal:  Middle East J Anaesthesiol       Date:  2009-06

Review 9.  Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position Paper on Sugammadex use.

Authors:  G Della Rocca; P Di Marco; L Beretta; A R De Gaudio; C Ori; P Mastronardi
Journal:  Minerva Anestesiol       Date:  2012-11-29       Impact factor: 3.051

10.  Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.

Authors:  Benoît Plaud; Olli Meretoja; Rainer Hofmockel; Julien Raft; Peter A Stoddart; Jacqueline H M van Kuijk; Yvonne Hermens; Rajinder K Mirakhur
Journal:  Anesthesiology       Date:  2009-02       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.